Close

"Great Scenario for KarXT" - Stifel Karuna Therapeutics (KRTX) at Buy Aug 8, 2022 07:07AM
"Near Term Focus Remains on Upcoming Schizophrenia Data; Risk/Reward Remains Compelling" - Mizuho Securities Reiterates Karuna Therapeutics (KRTX) at Buy with $15 Price Target May 26, 2022 05:47AM
Stifel Reiterates Buy Rating on Karuna Therapeutics Inc. (KRTX) May 25, 2022 11:05AM
KRTX "Remains One of Top SMID Cap Picks" on KarXT's Potential, Model 75% Probability of Success - Karuna Therapeutics (KRTX) PT Hiked to $190 at Mizuho Securities\ Apr 27, 2022 05:58AM